Related Experiment Video
Updated: Sep 8, 2025

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Transcatheter edge-to-edge repair for the management of secondary mitral regurgitation - CRT 2025 Beyond the
Dan Haberman1, Michael J Reardon2, Gregg W Stone3
1Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
Insights
Secondary mitral regurgitation (SMR) in heart failure (HF) is common and serious. New evidence suggests transcatheter edge-to-edge repair (TEER) may benefit more patients beyond current guidelines.
Area of Science:
- Cardiology
- Interventional Cardiology
- Heart Failure Management
Background:
- Secondary mitral regurgitation (SMR) is a frequent complication of heart failure (HF).
- SMR significantly worsens prognosis despite guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy.
- Current guidelines limit transcatheter edge-to-edge repair (TEER) to severe, refractory SMR.
Purpose of the Study:
- To review current evidence and expert opinions on expanding TEER indications for SMR.
- To identify knowledge gaps and future research directions for SMR management.
- To inform upcoming guideline revisions for SMR treatment.
Main Methods:
- Expert panel discussion at the 2025 Cardiovascular Research Technologies (CRT) conference.
- Review of recent pivotal randomized controlled trials (RESHAPE-HF2, MATTERHORN, EFFORT).
- Analysis of emerging evidence in diverse clinical scenarios.
Main Results:
- Unresolved questions exist regarding TEER in moderate SMR, asymptomatic patients, and specific HF subsets.
- Registry and observational data suggest procedural safety and clinical benefit of TEER in broader populations.
- Consensus supports the need for dedicated trials in specific SMR subgroups.
Conclusions:
- Existing guidelines may not fully encompass the evolving role of TEER in SMR.
- Further randomized trials are needed to clarify TEER efficacy in moderate and asymptomatic SMR.
- Broader consideration of TEER, guided by real-world data, is warranted for SMR management.
Abstract:
Secondary mitral regurgitation (SMR) remains a prevalent and challenging complication in patients with heart failure (HF), associated with poor prognosis despite optimal guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy. Current American and European guidelines recommend GDMT as first-line therapy, with transcatheter edge-to-edge repair (TEER) reserved for severe symptomatic SMR patients who remain refractory. However, both guidelines preceded the reporting of pivotal randomized controlled trials (RESHAPE-HF2, MATTERHORN, and EFFORT) and emerging evidence in new clinical scenarios. At the 2025 Cardiovascular Research Technologies (CRT) conference, the session "Beyond the Guidelines" convened an expert panel to address existing gaps and evolving indications. Discussions highlighted unresolved questions regarding TEER in moderate SMR, asymptomatic patients, atrial functional MR, cardiogenic shock, and as a bridge in end-stage HF. Panel consensus emphasized the need for dedicated randomized trials in these subgroups and consideration of broader TEER use based on registry and observational data demonstrating procedural safety and clinical benefit. This review summarizes current evidence, knowledge gaps, and expert perspectives to inform future guideline development and optimize management of SMR across the spectrum of HF.
Related Concept Videos
Mitral Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Mitral Regurgitation IV: Nursing Management
Mitral Valve Prolapse II: Assessment and Management
Mitral Regurgitation I: Introduction
Mitral Regurgitation II: Clinical Features and Diagnostic Tests

